391 related articles for article (PubMed ID: 19825819)
21. Miltefosine for new world cutaneous leishmaniasis.
Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
[TBL] [Abstract][Full Text] [Related]
22. Combined interleukin-12 and topical chemotherapy for established Leishmaniasis drastically reduces tissue parasitism and relapses in susceptible mice.
Fernandes AP; Carvalho FA; Tavares CA; Santiago HC; Castro GA; Tafuri WL; Ferreira LA; Gazzinelli RT
J Infect Dis; 2001 Jun; 183(11):1646-52. PubMed ID: 11343214
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases.
Nakayama H; Loiseau PM; Bories C; Torres de Ortiz S; Schinini A; Serna E; Rojas de Arias A; Fakhfakh MA; Franck X; Figadère B; Hocquemiller R; Fournet A
Antimicrob Agents Chemother; 2005 Dec; 49(12):4950-6. PubMed ID: 16304157
[TBL] [Abstract][Full Text] [Related]
24. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
[TBL] [Abstract][Full Text] [Related]
25. Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis.
Neira LF; Mantilla JC; Escobar P
J Antimicrob Chemother; 2019 Jun; 74(6):1634-1641. PubMed ID: 30815688
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the efficacy of systemic miltefosine associated with photodynamic therapy with liposomal chloroaluminium phthalocyanine in the treatment of cutaneous leishmaniasis caused by Leishmania (L.) amazonensis in C57BL/6 mice.
Ribeiro JBP; Miranda-Vilela AL; Graziani D; Gomes MRA; Amorim AAS; Garcia RD; de Souza Filho J; Tedesco AC; Primo FL; Moreira JR; Lima AV; Sampaio RNR
Photodiagnosis Photodyn Ther; 2016 Mar; 13():282-290. PubMed ID: 26306406
[TBL] [Abstract][Full Text] [Related]
27. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions.
Schwartz J; Moreno E; Calvo A; Blanco L; Fernández-Rubio C; Sanmartín C; Nguewa P; Irache JM; Larrea E; Espuelas S
J Dermatol Sci; 2018 Oct; 92(1):78-88. PubMed ID: 30037731
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological evaluation of anti-leishmanial activity by in vivo nitric oxide modulation in Balb/c mice infected with Leishmania major MRHO/IR/75/ER: an Iranian strain of cutaneous leishmaniasis.
Nahrevanian H; Farahmand M; Aghighi Z; Assmar M; Amirkhani A
Exp Parasitol; 2007 Jul; 116(3):233-40. PubMed ID: 17335813
[TBL] [Abstract][Full Text] [Related]
29. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
Calvopina M; Gomez EA; Sindermann H; Cooper PJ; Hashiguchi Y
Am J Trop Med Hyg; 2006 Dec; 75(6):1074-7. PubMed ID: 17172368
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous leishmaniasis treatment.
Minodier P; Parola P
Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
[TBL] [Abstract][Full Text] [Related]
31. Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
Hendrickx S; Van den Kerkhof M; Mabille D; Cos P; Delputte P; Maes L; Caljon G
PLoS Negl Trop Dis; 2017 May; 11(5):e0005620. PubMed ID: 28505185
[TBL] [Abstract][Full Text] [Related]
32. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
[TBL] [Abstract][Full Text] [Related]
34. First case of typical Old World cutaneous leishmaniasis treated with miltefosine.
Stojkovic M; Junghanss T; Krause E; Davidson RN
Int J Dermatol; 2007 Apr; 46(4):385-7. PubMed ID: 17442078
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
Soto J; Rea J; Balderrama M; Toledo J; Soto P; Valda L; Berman JD
Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
[TBL] [Abstract][Full Text] [Related]
36. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis.
Ben Salah A; Ben Messaoud N; Guedri E; Zaatour A; Ben Alaya N; Bettaieb J; Gharbi A; Belhadj Hamida N; Boukthir A; Chlif S; Abdelhamid K; El Ahmadi Z; Louzir H; Mokni M; Morizot G; Buffet P; Smith PL; Kopydlowski KM; Kreishman-Deitrick M; Smith KS; Nielsen CJ; Ullman DR; Norwood JA; Thorne GD; McCarthy WF; Adams RC; Rice RM; Tang D; Berman J; Ransom J; Magill AJ; Grogl M
N Engl J Med; 2013 Feb; 368(6):524-32. PubMed ID: 23388004
[TBL] [Abstract][Full Text] [Related]
37. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
Moosavi Z; Nakhli A; Rassaii S
Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
[No Abstract] [Full Text] [Related]
38. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial.
Asilian A; Davami M
Clin Exp Dermatol; 2006 Sep; 31(5):634-7. PubMed ID: 16780497
[TBL] [Abstract][Full Text] [Related]
39. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis.
Eissa MM; Amer EI; El Sawy SM
Exp Parasitol; 2011 Aug; 128(4):382-90. PubMed ID: 21620834
[TBL] [Abstract][Full Text] [Related]
40. The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.
Bäumer W; Wlaź P; Jennings G; Rundfeldt C
Eur J Pharmacol; 2010 Feb; 628(1-3):226-32. PubMed ID: 19917276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
